Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Accumulated Depreciation & Amortization rose 4210.53% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 4210.53%. This contributed to the annual value of $7.2 million for FY2024, which is 4693.88% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization is $2.7 million, which was up 4210.53% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization peaked at $8.0 million during Q3 2022, and registered a low of $1.1 million during Q1 2023.
  • For the 5-year period, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $3.6 million, with its median value being $3.2 million (2021).
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 20035.06% in 2021, then crashed by 8500.37% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Accumulated Depreciation & Amortization stood at $3.2 million in 2021, then grew by 21.88% to $3.9 million in 2022, then grew by 25.64% to $4.9 million in 2023, then surged by 46.94% to $7.2 million in 2024, then tumbled by 62.5% to $2.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $2.7 million for Q3 2025, versus $4.5 million for Q2 2025 and $2.0 million for Q1 2025.